Transition of products to the EU Medical Device Regulation

Expansion of the operating area at the location

Continuous progress in international market approach and product development

Enhancement of machinery and modernization

Expansion of the clean room, development of OEM services

Expansion of OEM production

Expansion of the warming product range, intensified development work for BAXTER, exterior refurbishment

Corporate video in the form of an electronic business card.
Electrical stimulation redesigned.
Strengthening of Biegler's market presence in Austria

Implementation of a new ERP program, corporate design improved, blood warmer range redesigned

Expansion of OEM products with EMCOOLS cooling pad system for emergency medicine, project planning for new building

FDA approval granted for P-STIM and start of US market cultivation, launch of new application system for fibrin sealant

OEM campaign, new OEM partners, FDA approval process for P-STIM

OEM campaign, new OEM partners

Production streamlining, expansion of the export markets for new products.

Additional purchase of more land adjoining the existing premises as an expansion option.
Development of a new therapy device for the inspiratory muscles in chronic obstructive pulmonary diseases.
Transition of point stimulation to production.

Acquisition of additional machining centers in the mechanical, machining production division, entry into SMD technology as part of electronic manufacturing.

Implementation of a class 100,000 clean room production area for sterile disposable products (catheters, application systems for fibrin sealant). Expansion of the plastic injection molding technology division, in terms of both space and machinery.

Inclusion of another OEM product (respiratory nebulizer) for Siemens in Solna, Sweden.
Product expansion in infusion technology for surgical medicine and intensive care.
Start of development work for point stimulation.

Opening of a new research and development division, plus additional storage and conference rooms in another new production and office building.

Purchase of land to permit the expansion of the mechanical production plant.

Plastics division premises expanded and new production facility constructed.

Production and assembly premises developed.

On the basis of the structural improvement law (promotion of enterprises), Biegler was transformed into a GesmbH [limited liability company].

Collaboration with Immuno (now the US Baxter Group) with respect to fibrin sealant resulted in an expansion of our product range.

Foundation